Last updated: February 20, 2026
What are the main suppliers manufacturing STALEVO 150?
STALEVO 150, a combination medication containing levodopa, carbidopa, and entacapone, is primarily supplied by Novartis. The drug is marketed under the brand name STALEVO 150, with Novartis holding the patent and manufacturing rights since its approval.
Who are the authorized manufacturing and distribution entities?
| Supplier Category |
Entities |
Notes |
| Original Manufacturer |
Novartis |
Controls patent rights, primary producer, and distributor in global markets. |
| Generic Manufacturers |
Multiple (varies by region) |
After patent expiry or licensing agreements, generics manufacturers produce versions of STALEVO 150. These entities include pharmaceutical firms in India, China, and other regions with active generics markets. |
| Licensed Distributors |
Regional distributors authorized by Novartis or generics firms |
Responsible for supply chain logistics within specific territories. |
Patent and Market Status
| Year of Patent Expiry |
Regulatory Status |
Notes |
| 2018 (approximate) |
Patent expiry in several jurisdictions |
Opens market for generic versions. Actual expiry varies by country. |
| Post-2018 |
Availability of generics |
Multiple firms introduced biosimilar versions or generics, often under local regulatory approvals. |
Notable Regional Suppliers
-
Europe: Novartis maintains direct supply in key European markets, including Germany, the UK, and France. Generics produced in countries such as India and China are available through licensed distributors.
-
United States: No FDA-approved generic versions due to patent exclusivity. Novartis remains the sole supplier.
-
Asia: India’s Sun Pharmaceutical and Lupin are among the leading generics manufacturers producing STALEVO 150 after patent expiry.
-
Emerging Markets: Generics produced by local pharmaceutical firms often under licensing agreements with Novartis or independently developing bioequivalent versions.
Supply Chain and Distribution Channels
The primary supply route involves Novartis's manufacturing plants located in Europe, India, and other regions. Once produced, distribution occurs via regional partners or direct shipments to wholesalers, pharmacies, and hospitals. After patent expiry, local licensing agreements enable regional firms to produce and distribute biosimilars, increasing market availability.
Conclusion
STALEVO 150 is predominantly supplied by Novartis. Post-patent expiry, multiple regional generic manufacturers have entered the market, notably in India and China. The availability of generics depends on patent status and regional regulatory approval processes.
Key Takeaways
- Novartis is the exclusive supplier of STALEVO 150 until patent expiry.
- Patent expiry around 2018 allowed global generics manufacturers to start producing biosimilars.
- Regional suppliers include Sun Pharmaceutical, Lupin (India), and other firms with licensing agreements.
- Supply channels involve direct manufacturing, licensing, and regional distribution networks.
- Market access for generics varies based on patent laws and regulatory approvals per country.
FAQs
1. Is STALEVO 150 available as a generic?
Yes, in regions where patent protection has expired, multiple generic versions are available.
2. Who controls the manufacturing of STALEVO 150?
Novartis holds the original patent and manufacturing rights; regional generics manufacturers produce biosimilars post-expiry.
3. Which countries have the highest availability of STALEVO 150?
Europe and North America primarily rely on Novartis. India and China have several licensed generics.
4. Are there approved biosimilars in the U.S.?
No, the FDA has not approved generic versions of STALEVO 150 due to patent protections.
5. How does regional regulation affect STALEVO 150 supply?
Regulatory approvals determine whether generics can be marketed, influencing supply diversity across countries.
References
- Novartis. (2022). Product information for STALEVO. Retrieved from https://www.novartis.com
- U.S. Food and Drug Administration. (2022). Approved drug products with therapeutic equivalence evaluations. FDA.gov
- Indian Pharmacopoeia Commission. (2021). List of approved generic manufacturers. IPC.gov.in
